360775-96-8

Basic information

• Product Name: 2-Hydroxymethyl-6-[2-(4-methoxy-benzyl)-phenoxy]-tetrahydro-pyran-3,4,5-triol
• Synonyms: 2-Hydroxymethyl-6-[2-(4-methoxy-benzyl)-phenoxy]-tetrahydro-pyran-3,4,5-triol
• CAS NO: 360775-96-8
• Molecular Formula: C₂₀H₂₄O₇
• Molecular Weight: 376
• Mol File: 360775-96-8.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Hydroxymethyl-6-[2-(4-methoxy-benzyl)-phenoxy]-tetrahydro-pyran-3,4,5-triol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Hydroxymethyl-6-[2-(4-methoxy-benzyl)-phenoxy]-tetrahydro-pyran-3,4,5-triol(360775-96-8)
• EPA Substance Registry System: 2-Hydroxymethyl-6-[2-(4-methoxy-benzyl)-phenoxy]-tetrahydro-pyran-3,4,5-triol(360775-96-8)

Safety Data

• Hazardous Substances Data: 360775-96-8(Hazardous Substances Data)

Upstream product

• 360775-87-7 2-[(4-methoxyphenyl)methyl]phenyl 2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside 
• 7234-29-9 2-iodophenyl β-D-glucopyranoside 
• 824-94-2 p-methoxybenzyl chloride 
• 572-09-8 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl bromide 
• 37155-50-3 2-(4-methoxybenzyl)phenol 
• 604-69-3 β-D-glucose pentaacetate 
• 3947-62-4 2,3,4,5-tetra-O-acetyl-D-glucopyranose 
• 21615-34-9 2-Methoxybenzoyl chloride 
• 100-66-3 methoxybenzene 
• 92052-29-4 2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl trichloroacetimidate 
• 18733-07-8 (2-hydroxyphenyl)(4-methoxyphenyl)methanone 
• 108-95-2 phenol 
• 90-02-8 salicylaldehyde 
• 85604-67-7 2-(tetrahydropyran-2-yloxy)benzaldehyde 

Downstream Products

• 408504-26-7 Sergliflozin etabonate 
• 408504-27-8 2-{[4-(methyloxy)phenyl]methyl}phenyl-6-O-[(methyloxy)carbonyl]-β-D-glucopyranoside 
• 866476-37-1 2-[(4-methoxyphenyl)methyl]phenyl 6-O-(1,1-dimethylethyl)-β-D-glucopyranoside 

Relevant articles and documents

Discovery of Salidroside-Derivated Glycoside Analogues as Novel Angiogenesis Agents to Treat Diabetic Hind Limb Ischemia

Therapeutic angiogenesis is a potential therapeutic strategy for hind limb ischemia (HLI); however, currently, there are no small-molecule drugs capable of inducing it at the clinical level. Activating the hypoxia-inducible factor-1 (HIF-1) pathway in skeletal muscle induces the secretion of angiogenic factors and thus is an attractive therapeutic angiogenesis strategy. Using salidroside, a natural glycosidic compound as a lead, we performed a structure-activity relationship (SAR) study for developing a more effective and druggable angiogenesis agent. We found a novel glycoside scaffold compound (C-30) with better efficacy than salidroside in enhancing the accumulation of the HIF-1α protein and stimulating the paracrine functions of skeletal muscle cells. This in turn significantly increased the angiogenic potential of vascular endothelial and smooth muscle cells and, subsequently, induced the formation of mature, functional blood vessels in diabetic and nondiabetic HLI mice. Together, this study offers a novel, promising small-molecule-based therapeutic strategy for treating HLI.

Modification on the O-glucoside of Sergliflozin-A: A new strategy for SGLT2 inhibitor design

Poor pharmacokinetic stability is one of the issues of O-glucoside SGLT2 inhibitors in clinical trials, hence C-glucoside inhibitors have been developed and extensively applied. Herein, we provided an alternative approach to improve the pharmacokinetic st

Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same

The present invention relates to glucopyranosyloxybenzylbenzene derivatives represented by the general formula: wherein P represents a group forming a prodrug; and R represents a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a lower al